<DOC>
	<DOC>NCT02905916</DOC>
	<brief_summary>The purpose of the trail is to evaluate the efficacy and safety of PEG-rhG-CSF in primary prophylaxis and secondary prophylaxis of neutropenia after chemotherapy.</brief_summary>
	<brief_title>The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1. Patients with age between 18 and 70 years. 2. Breast cancer, lymphoma, bone tumor or Gynecologic tumor patients. 3. With multicycle chemotherapy. 4. With III/IV degree neutropenia after the last cycle of chemotherapy and plans to use the same regimen in the subsequent cycles.FN risk of the chemotherapy regimens is ≥20%，or 10%≤FN risk＜20% and has high risk factors associated with FN. 5. KPS score≥ 70. 6. Expected to survive more than 3 months. 7. No hematologic system disease and ANC≥1.5×10E9/L, PKT≥80×10E9/L, Hb≥ 75g/L, WBC≥3×10E9/L, and no bleeding tendency. 8. Written informed consent are acquired. 1. With infection or systemic antibiotic therapy 72h before chemotherapy. 2. With any abnormal hematopoietic function. 3. Received transplantation within 3 months. 4. Suffered from other malignant tumor or brain metastases. 5. TBIL, ALT,AST &gt; 2.5×ULN; if it were caused by liver metastases, TBIL, ALT,AST &gt;5×ULN. 6. Cr &gt;1.5 ×ULN. 7. Sensitive to the product or other genetically engineered biological products from Escherichia coli strains. 8. Mental or nervous system disorders. 9. Refused to accept contraceptive measures. 10. Other situations that investigators consider as contraindication for this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>